Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2.
about
Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptorSiglecs in the immune systemGenetics ignite focus on microglial inflammation in Alzheimer's diseaseEvidence for C1q-mediated crosslinking of CD33/LAIR-1 inhibitory immunoreceptors and biological control of CD33/LAIR-1 expression.Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma.The role of Siglec-1 and SR-BI interaction in the phagocytosis of oxidized low density lipoprotein by macrophages.CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in miceThe evolving biology of microglia in Alzheimer's disease.Group B Streptococcus engages an inhibitory Siglec through sialic acid mimicry to blunt innate immune and inflammatory responses in vivoSurface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cellsDistinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity.LST1/A is a myeloid leukocyte-specific transmembrane adaptor protein recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to the plasma membrane.Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinMolecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune responseInduction of myelodysplasia by myeloid-derived suppressor cells.Basic and clinical immunology of SiglecsAnti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.Glycobiology of immune responsesExpression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.CD72 regulates the growth of KIT-mutated leukemia cell line Kasumi-1.Human Siglec-5 inhibitory receptor and immunoglobulin A (IgA) have separate binding sites in streptococcal beta protein.The Alzheimer's Disease-protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool.Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858Enhanced lentiviral vector production in 293FT cells expressing Siglec-9.Frozen cord blood hematopoietic stem cells differentiate into higher numbers of functional natural killer cells in vitro than mobilized hematopoietic stem cells or freshly isolated cord blood hematopoietic stem cells.Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia.Regulation of Siglec-8-induced intracellular reactive oxygen species production and eosinophil cell death by Src family kinases.
P2860
Q24532754-DF73C7A5-FA93-41BE-8CE5-A4BD3A90441CQ24682458-AA6AFA82-57BF-4AAD-B1CF-3F1309E588B6Q26781865-7704157F-F6A9-46F4-88F1-5B32413A871FQ33625486-7EC512DF-534C-4C0C-B7D7-7049FF080457Q33786986-14E8ACCB-D5AC-4CEB-9857-925F6F310417Q34631933-A1EFCE17-DEA3-429C-A528-964B37CFA414Q35019914-D75FBE4D-B430-4EF2-880D-364F84E7E634Q35064995-50533DF6-EC23-4F61-8070-FEC44DB2EA1FQ35082207-7443438F-26C4-41DC-B727-848E37C7A2AAQ35895107-3E6AD271-F16B-4D00-A12F-17C1EA2DEC63Q35950210-A0C55703-EE87-494B-9D69-8412578C7A70Q36080432-4113AC4F-E3FF-49B1-96D6-B112345F9DBFQ36498399-5A8D8258-01C3-499C-ACA5-0A8B59146B3EQ36932014-FA1AA986-6DE8-4D6C-810F-A4D835D5C1ABQ37151185-00198D37-7996-4396-833C-070F3FA991FEQ37259216-48163A3E-5BBC-464C-9ABF-378BDE7DDA04Q37348437-48B902D2-04DD-453A-BFAF-B95883CA05A9Q37381414-4F5181E9-CE75-4D55-968E-034CA0465FDAQ37448685-A55E8C6B-D244-4C86-AC7D-51D88E60114CQ37536546-66019EFA-88AA-4DEB-B16E-1A4519A2FDEDQ37600827-41ADA42C-78BE-494F-9A65-B815AC0CE763Q37693415-1F919AAF-F735-4F91-A9F3-E43858E9C4DDQ38674244-3DDC8881-F6C8-415E-A842-7BB960120803Q38696318-7C769D40-91C3-4774-8A9D-1205461CA8ACQ41350670-736848A6-84DE-4429-B0AC-66B9BDF7E4D4Q41835254-4502AF6A-9C76-432A-BB60-F0EF4E029D85Q41898844-993267B6-F3D0-452D-B267-C78767F3D053Q41925220-CDD06796-9AF4-45B3-8639-7AB87B4CF974Q46484443-0306EDD6-76ED-4E1B-BDB2-C03C645779C6
P2860
Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Myeloid specific human CD33 is ...... phosphatases SHP-1 and SHP-2.
@en
type
label
Myeloid specific human CD33 is ...... phosphatases SHP-1 and SHP-2.
@en
prefLabel
Myeloid specific human CD33 is ...... phosphatases SHP-1 and SHP-2.
@en
P2093
P1433
P1476
Myeloid specific human CD33 is ...... e phosphatases SHP-1 and SHP-2
@en
P2093
P304
P407
P577
2000-07-01T00:00:00Z